NCT06170242Phase 2Completed

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Study sponsor: Enanta Pharmaceuticals, Inc · ENTA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-06-17Actual
Enrollment · participants142Actual
Source updated2025-10-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview